scispace - formally typeset
E

E. Jonasch

Researcher at University of Texas Health Science Center at Houston

Publications -  19
Citations -  5274

E. Jonasch is an academic researcher from University of Texas Health Science Center at Houston. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 6, co-authored 19 publications receiving 4842 citations.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study.

TL;DR: Frontline sunitinib has been shown to produce a high response rate (RR), and improved progression-free survival (PFS) and overall survival (OS) in patients with clear cell RC...
Journal ArticleDOI

A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis

TL;DR: Sorafenib was shown to significantly prolong progression-free survival (PFS) in pts with mRCC after cytokine failure and low-dose interferon alfa (IFN-α) showed similar results.
Journal ArticleDOI

Outcome of patients (pts) with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience.

TL;DR: The prognosis of RMC pts remains poor despite initial palliation with systemic therapy, and collaborative multi-institutional efforts are needed to better understand the biology of this disease and improve treatment strategies.
Journal ArticleDOI

Schedule modifications and treatment outcomes for sunitinib-related adverse events.

TL;DR: A retrospective review of mRCC pts in an outpatient clinic was performed to identify schedule modifications (SM) that maintained dose intensity while decreasing AEs, and the impact of SM on 6 mo follow-up (f/u).